December 05, 2016 4:22 AM ET

Pharmaceuticals

Company Overview of Fresenius Kabi USA, LLC

Company Overview

Fresenius Kabi USA, LLC develops, manufactures, and delivers pharmaceuticals and medical devices for critically and chronically ill patients. The company specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. It offers pharmaceuticals used in the treatment of various therapeutic areas, such as anti-infective, anesthesia/analgesia, critical care, and oncology for hospitals, long-term care facilities, alternate care sites, and clinics in North America. The company also provides medical devices in the areas of transfusion technologies, infusion pumps, therapeutic apheresis, plasmapheresis system, and cell processing. It sells its products through...

3 Corporate Drive

Lake Zurich, IL 60047

United States

Founded in 1996

Phone:

847-550-2300

Key Executives for Fresenius Kabi USA, LLC

Chief Executive Officer and President
Chief Financial Officer and Executive Vice President
Chief Operating Officer and Executive Vice President
Age: 61
President of Pharmaceuticals of North America Region
Age: 57
President of Medical Devices - Region North America
Compensation as of Fiscal Year 2016.

Fresenius Kabi USA, LLC Key Developments

Fresenius Kabi Receives FDA 510(k) Clearance for the Aurora Xi Plasmapheresis System

Fresenius Kabi announced that it has received FDA 510(k) clearance for the Aurora™ Xi Plasmapheresis System. Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. Plasma is the liquid portion of blood that contains valuable proteins used to treat burn victims, bleeding disorders, human immune deficiencies, and other chronic or genetic disorders. Patients who rely on plasma protein therapies often require regular infusions or injections throughout their lives. Source Plasma is collected exclusively through plasmapheresis, an automated process in which plasma is taken from donated blood and the remaining components – primarily red cells and platelets – are returned to the donor. Source Plasma is used by pharmaceutical companies to manufacture plasma-based therapies, such as albumin and intravenous immunoglobulin (IVIG).

Fresenius Kabi Announces the Immediate Availability in the United States of Ketorolac Tromethamine Injection

Fresenius Kabi announced the immediate availability in the United States of Ketorolac Tromethamine Injection (15 mg/mL) in the company’s Simplist ready-to-administer prefilled syringe. Ketorolac Tromethamine Injection is now available in 15 mg/mL Simplist prefilled syringes - the ready-to-administer product line exclusively from Fresenius Kabi. Fresenius Kabi now offers ready-to-administer syringes of Ketorolac Tromethamine Injection in three strengths: 15mg/mL, 30 mg/mL and 60 mg/2mL.

Fresenius Kabi to Invest Approximately $250 Million over 10 Years to Expand its Melrose Park Site

Fresenius Kabi announced it will invest approximately $250 million over 10 years to expand the company’s Melrose Park site which manufactures generic, sterile injectable pharmaceuticals used in hospitals and clinics throughout the United States. The expansion of the current Melrose Park site into a manufacturing campus is a multi-stage, multi-year project with ground breaking planned for 2017 and final project completion in 2026. The current entrance to Fresenius Kabi's pharmaceutical manufacturing location in Melrose Park, Illinois. The company plans to spend $250 million to expand the site for the continued manufacturing of generic injectable medicines. The plant produces a broad range of generic injectable medicines used to treat critically and chronically ill patients. The expansion will create multiple new buildings connected to the existing manufacturing site and will feature fully automated aseptic filling lines using isolator technology, expanded lyophilization (freeze-drying) capabilities, formulation areas, a dedicated warehouse for raw materials and components and an administration building with conference center, laboratories, office space and cafeteria. In addition to its Melrose Park locations, Fresenius Kabi has multiple locations in Illinois including Bensenville, Skokie and Lake Zurich. The company also has manufacturing sites in New York, North Carolina and Pennsylvania and employs more than 2,500 people in the United States.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 8, 2016
Becton, Dickinson and Company, BD Rx Business
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fresenius Kabi USA, LLC, please visit www.fresenius-kabi.us. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.